This study is designed to explore the safety of RD13-01 for patients with CD7+ relapsed and/or refractory T cell acute lymphoblastic leukemia or lymphoblastic lymphoma. And to evaluate the efficacy and pharmacokinetics of RD13-01 in patients.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
24
Universal CAR-T cells targeting CD7
Hebei Yanda Ludaopei Hospital
Langfang, Hebei, China
RECRUITINGDose-limiting toxicity (DLT)
Time frame: 4 weeks after infusion
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.